This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Centene (CNC) Wins Medi-Cal Contracts but Loses 3 Counties
by Zacks Equity Research
Centene (CNC) is likely to appeal the decision to avoid disruption in services and it has time until Sep 1, 2022, to do so.
Buy These 5 Stocks With Upgraded Broker Ratings Right Away
by Swayta Shah
As brokers have a deeper understanding of the stocks, one must follow rating upgrades. We pick BJ's Wholesale Club (BJ), Elevance Health (ELV), MGIC Investment (MTG), Mercer International (MERC) and RCM Technologies (RCMT) as these witness rating upgrades.
Humana (HUM) Brand to Open Senior-Centric Centers in Arizona
by Zacks Equity Research
Humana's (HUM) CenterWell brand announces plans to open nine centers by early 2023 to serve the aging population of the Phoenix region.
Looking for a Growth Stock? 3 Reasons Why Elevance Health (ELV) is a Solid Choice
by Zacks Equity Research
Elevance Health (ELV) possesses solid growth attributes, which could help it handily outperform the market.
Pediatrix (MD) Up 8% Since Q2 Earnings Release, Revenues Up Y/Y
by Zacks Equity Research
Pediatrix's (MD) second-quarter results reflect growth in patient volumes. Adjusted EBITDA is expected within $260-$270 million for 2022.
Cigna (CI) & Oscar Health Boost Presence in Philadelphia
by Zacks Equity Research
Cigna (CI) & Oscar Health's plans are likely to target businesses with 1-50 employees.
UnitedHealth (UNH) Unit Adds Features to Surest Plans
by Zacks Equity Research
UnitedHealth Group's (UNH) arm UnitedHealthcare advances Surest plans by including features to lure more employers into opting for the attractive package and bolster its geographic reach.
Are Medical Stocks Lagging Alkermes (ALKS) This Year?
by Zacks Equity Research
Here is how Alkermes (ALKS) and Elevance Health (ELV) have performed compared to their sector so far this year.
Ensign Group (ENSG) Stock Up 6% Since Q2 Earnings Release
by Zacks Equity Research
Ensign Group's (ENSG) second-quarter results reflect revenue growth, and solid contributions from the Skilled Services and Standard Bearer segments. A hiked 2022 EPS guidance bodes well.
Encompass Health (EHC) Up 4.7% Despite Q2 Earnings Miss
by Zacks Equity Research
Encompass Health (EHC) intends to open three additional de novo locations and increase the bed count by 20 in existing facilities this year.
ELV vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Community Health (CYH) Down 30.3% Since Q2 Earnings Report
by Zacks Equity Research
Community Health (CYH) expects capex to remain within $400-$450 million in 2022.
Teladoc (TDOC) Down 10.3% Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Teladoc (TDOC) projects total visits between 4.8 million and 5 million for the third quarter.
Humana (HUM) Q2 Earnings Beat Estimates, Ups '22 EPS View
by Zacks Equity Research
Humana's (HUM) second-quarter earnings benefit from higher premiums and strong individual Medicare Advantage membership growth. A hiked adjusted EPS guidance for 2022 is noteworthy.
3 Reasons Why Elevance Health (ELV) Is a Great Growth Stock
by Zacks Equity Research
Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ELV vs. GDRX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ELV vs. GDRX: Which Stock Is the Better Value Option?
Universal Health (UHS) Q2 Earnings Beat on Strong Segments
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from strong contributions from Acute Care Hospital Services and Behavioral Health Care Services segments, partly offset by elevated operating costs.
Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.
Tenet Healthcare (THC) Q2 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter earnings benefit from strong Ambulatory Care and Conifer segments. However, a trimmed EPS view for 2022 might raise concerns for investors.
HCA Healthcare (HCA) Q2 Earnings Beat on Better Patient Volumes
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter results reflect improved revenues stemming from better same-facility emergency room visits. However, the results were partly offset by elevated salaries and benefits cost.
Elevance Health (ELV) Q2 Earnings Beat on Higher Premiums
by Zacks Equity Research
Elevance Health (ELV) hikes adjusted net income estimate for this year to more than $28.70 per share.
Anthem (ELV) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Anthem (ELV) delivered earnings and revenue surprises of 4.15% and 0.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Medpace (MEDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Elevance Health (ELV) Beat Q2 Earnings on Membership Growth?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to reflect improved Commercial Business operations, driven by the robust growth in risk-based areas.
Anthem (ELV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Anthem (ELV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.